| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/02/2009 | WO2009040024A2 Use of bim-23127 and optionally urodilatin as therapeutic agents eg for the treatment of m. tuberculosis infections |
| 04/02/2009 | WO2009040023A2 Use of galnon as a therapeutic agent |
| 04/02/2009 | WO2009040022A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040021A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040020A1 Amylin as a therapeutic agent |
| 04/02/2009 | WO2009040019A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040018A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040017A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040006A1 Spantide for therapeutic uses |
| 04/02/2009 | WO2009040005A2 Use of the peptide rfmwmr as a therapeutic agent |
| 04/02/2009 | WO2009040004A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039996A2 Use of bradykinin alone or in combination with melanotan ii as a therapeutic agent |
| 04/02/2009 | WO2009039995A1 Big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039994A1 Proadrenomedullin alone or in combination with big gastrin i as a therapeutic agent |
| 04/02/2009 | WO2009039993A2 Use of melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039992A2 Use of band 3 protein (824-829) and/or melanocyte-stimulating hormone release-inhibiting factor as a therapeutic agent in the treatment of pseudomonas aeruginosa infection |
| 04/02/2009 | WO2009039991A2 Use of aviptadil as a therapeutic agent |
| 04/02/2009 | WO2009039990A2 Use of icam peptide as a therapeutic agent |
| 04/02/2009 | WO2009039989A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | WO2009039988A2 Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection |
| 04/02/2009 | WO2009039987A1 Use of peptide thr-thr-ser-gln-val-arg-pro-arg as a therapeutic agent |
| 04/02/2009 | WO2009039986A2 Use of the peptide asn-asp-asp-cys-glu- leu-cys-val-asn-val-ala-cys-thr-gly-cys-leu alone or in combination with the peptide thr-thr-ser-gln-val- arg-pro-αrg as a therapeutic agent |
| 04/02/2009 | WO2009039985A2 Therapeutic uses of urocortin ii |
| 04/02/2009 | WO2009039984A2 Therapeutic uses of urocortin ii and kisspeptin ( 27-54 ) |
| 04/02/2009 | WO2009039983A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039982A2 Use of gip alone or in combination with dynorphin b as a therapeutic agent |
| 04/02/2009 | WO2009039981A2 Use of (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039980A2 Use of bfgf 1-24 and optionally (arg 8) vasopressin to treat eg s. pneumoniae infection |
| 04/02/2009 | WO2009039979A1 Use of the peptide pro-gly-thr-cys-glu-ile-cys-ala-tyr-ala-ala-cys-thr-gly-cys as a therapeutic agent |
| 04/02/2009 | WO2009039978A2 Therapeutic use of neuropeptide ei and acth 7-38 and compositions thereof |
| 04/02/2009 | WO2009039977A2 Use of alpha-casein (90-96) as a therapeutic agent in eg the treatment of hbv infection |
| 04/02/2009 | WO2009039976A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009039974A2 Use of peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039973A2 Use of peptide arg-asn-ile-ala-glu-ile-ile-lys-asp-ile-oh or its combination with the peptide asp-arg-gly-asp-ser-oh as a therapeutic agent |
| 04/02/2009 | WO2009039971A2 Use of the peptide sfllr-oh and muramyl dipeptide as therapeutic agents |
| 04/02/2009 | WO2009039970A1 Use of bpp-b as a therapeutic agent |
| 04/02/2009 | WO2009039969A2 Use of a vla-4 inhibitor tetrapeptide, alone or in combination with bpp-b, as a therapeutic agent |
| 04/02/2009 | WO2009039968A2 Use of angiotensin iii as a therapeutic agent in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039966A2 Use of nf-kappab inhibitor sn50 and optionally angiotensin iii as therapeutic agents in the treatment of eg hbv infection |
| 04/02/2009 | WO2009039964A2 Use of glucagon-like peptide as a therapeutic agent |
| 04/02/2009 | WO2009039963A1 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent |
| 04/02/2009 | WO2009039960A1 Use of the peptide his-ser-leu-gly-lys-trp-leu-gly-his-pro-asp-lys-phe alone or in combination with the peptide gly-ard-gly-asp-asn-pro-oh as a therapeutic agent |
| 04/02/2009 | WO2009039959A1 Use of peptide wmnstgftkvcgappc as a therapeutic agent |
| 04/02/2009 | WO2009039958A1 Therapeutic uses of peptides ysaypdsvpmms and wmnstgftkvcgappc |
| 04/02/2009 | WO2009039957A2 Use of angiotensin ii as a therapeutic agent in the treatment of eg s. pneumoniae infection |
| 04/02/2009 | WO2009039704A1 A method for producing human kallikrein 1 |
| 04/02/2009 | WO2009019303A3 A process for the preparation or purification of olmesartan medoxomil |
| 04/02/2009 | WO2009002203A8 Polyfunctional fullerene c60 aminoacid derivatives |
| 04/02/2009 | WO2008156832A3 Renin inhibitors |
| 04/02/2009 | WO2008150565A3 Ranolazine for elevated brain-type natriuretic peptide |
| 04/02/2009 | WO2008110777A3 Modulators of vegf splicing as pro- and anti-angiogenic agents |
| 04/02/2009 | WO2008094905A3 Encapsulated hdl mimetic peptides |
| 04/02/2009 | US20090088555 44 Human Secreted Proteins |
| 04/02/2009 | US20090088477 Compounds and methods for leukotriene biosynthesis inhibition |
| 04/02/2009 | US20090088468 Novel epoprostenol formulation and method of making thereof |
| 04/02/2009 | US20090088464 Merged ion channel modulating compounds and Uses Thereof |
| 04/02/2009 | US20090088461 Methods of Treating or Preventing Cardiac Disease Associated With a High Fat Diet |
| 04/02/2009 | US20090088457 Primary Amines as Renin Inhibitors |
| 04/02/2009 | US20090088453 such as biphenyl-2-yl-carbamic acid 1- {2-[5-(4-carbamoylpiperidin-l-ylmethyl)thiophen-2-ylcarbamoyl]ethyl}piperidin-4-yl ester for treating pulmonary disorders (asthma, chronic obstructive pulmonary disease); anticholinergic agents; reduced side effects such as dry mouth and constipation |
| 04/02/2009 | US20090088438 NEW TYROSINE DERIVATIVES AS PPARy MODULATORS |
| 04/02/2009 | US20090088429 Isoquinoline Derivatives |
| 04/02/2009 | US20090088426 (3S,4R,5R)-3-hydroxymethyl-4-[4-((S)-3-methoxy-2-methyl-propoxymethyl)-phenyl]-5-[4-(3-methoxy-propyl)-3,4-dihydro-2H-benzo [1,4]oxazin-6-ylmethoxy]-piperidine-1-carboxylic acid benzyl ester; improvement of the pharmacokinetic properties; better bioavailability |
| 04/02/2009 | US20090088416 Deuterium-enriched lapaquistat |
| 04/02/2009 | US20090088404 Extended Release Pharmaceutical Formulations of S-Adenosylmethionine |
| 04/02/2009 | US20090088389 Novel x-conotoxin peptides (-ii) |
| 04/02/2009 | US20090088387 Composition for long-acting peptide analogs |
| 04/02/2009 | US20090088385 immunoglobulins; fibronectins; drug screening |
| 04/02/2009 | US20090088384 Therapeutic Fibrin-Derived Peptides And Uses Thereof |
| 04/02/2009 | US20090088368 Compositions comprising them as ppar modulators |
| 04/02/2009 | US20090087489 Imatinib compositions |
| 04/02/2009 | US20090087436 Compositions and methods for treating diseases |
| 04/02/2009 | US20090087422 Pharmaceutical composition for alleviation and treatment of ischemic conditions and method for delivering the same |
| 04/02/2009 | US20090087420 Stable solution of reduced coenzyme q |
| 04/02/2009 | US20090087415 Treatment of cardiovascular disorders using the cell differentiation signaling protein Nell1 |
| 04/02/2009 | US20090087412 Methods and compositions relating to HDAC 4 and 5 regulation of cardiac gene expression |
| 04/02/2009 | US20090087389 Dehydroepiandrosterone sulfate dihydrate inhalation compositions and methods |
| 04/02/2009 | DE102008049320A1 Use of v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma derived oncogene homolog (HER2/neu) antagonists for treating restenosis after angioplasty or after placing a stent into a vessel |
| 04/02/2009 | DE102007045476A1 Neue heteroarylsubstituierte Acetonderivate, geeignet zur Hemmung der Phospholipase A2 New heteroaryl acetone derivatives useful for inhibiting phospholipase A2 |
| 04/02/2009 | CA2700613A1 Angiogenic cells from human placental perfusate |
| 04/02/2009 | CA2700277A1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 04/02/2009 | CA2700274A1 Quinone derivatives, pharmaceutical compositions, and uses thereof |
| 04/02/2009 | CA2700113A1 Indazole acrylic acid amide compound |
| 04/02/2009 | CA2700088A1 Quinolone derivative |
| 04/02/2009 | CA2699244A1 Use of the peptide gly-arg-gly-asp-asn-pro as a therapeutic agent |
| 04/02/2009 | CA2699241A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699177A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699170A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699154A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699153A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699101A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699100A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699077A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699073A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699069A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699068A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699065A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699055A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699054A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699052A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | CA2699049A1 Use of a peptide as a therapeutic agent |